GEM-SUBSTITUTED ALPHA V BETA 3 INTEGRIN ANTAGONISTS
申请人:Pharmacia Corporation
公开号:EP1313705A1
公开(公告)日:2003-05-28
US6531494B1
申请人:——
公开号:US6531494B1
公开(公告)日:2003-03-11
[EN] GEM-SUBSTITUTED alpha v beta 3 INTEGRIN ANTAGONISTS<br/>[FR] ANTAGONISTES DE L'INTEGRINE DOLLAR G(A)V DOLLAR G(B)3 GEM-SUBSTITUES
申请人:PHARMACIA CORP
公开号:WO2002018340A1
公开(公告)日:2002-03-07
The present invention relates to a class of compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of Formula (I), and methods of selectively inhibiting or antagonizing the αvβ3 and/or the αvβ5 integrin.
Gem-substituted &agr;v&bgr;3 antagonists
申请人:Pharmacia Corporation
公开号:US06531494B1
公开(公告)日:2003-03-11
The present invention relates to a class of compounds represented by the Formula I.
or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr;V&bgr;3 and/or the &agr;V&bgr;5 integrin.
The present invention relates to a class of compounds represented by the Formula I.
1
or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr;
v
&bgr;
3
and/or the &agr;
v
&bgr;
5
integrin.